Biotechnology company United Therapeutics Corporation (UTHR) Monday said it received a second complete response letter from the United States Food and Drug Administration or FDA declining to approve its new drug application for treprostinil diolamine extended release tablets for the treatment of pulmonary arterial hypertension. The company has planned to immediately request an "end of review" meeting with the FDA to discuss this complete response letter.
However, Martine Rothblatt, chief executive officer of United Therapeutics said, "We remain confident that oral treprostinil will play an important role in treating PAH and we are committed to working collaboratively with the FDA to accomplish this goal in the most timely and appropriate manner."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.